Surface Oncology Inc

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune evasion.

Atai Life Sciences BV

Butterfly Network

3D Systems

StoneCo

Cathie Wood remains bullish on staple ARK names like Tesla and Teladoc. Still, the fund manager has added several new companies to her ETFs.

5 New Cathie Wood Stocks to Watch Right Now

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company's board of directors. Dr. Brunn brings more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies around the globe.

Surface Oncology Appoints Carsten Brunn to Board of Directors

- Non-clinical findings further support the potential of SRF388 to treat patients suffering from liver cancer -

Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company granted non-qualified stock options to two new employees to purchase an aggregate of 23,600 shares of the company's common stock with a per share exercise price of $1.72, the closing price of Surface's common stock as reported by Nasdaq on June 1, 2022, the date of grant.

Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences:

Surface Oncology to Participate in Upcoming Investor Conferences

– SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC –

Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Surface Oncology has been a major drag for investors. There's no bad news, but there's no good news either.

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will share a clinical update on SRF388 in an oral presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, to be held June 3-7, 2022 in Chicago, Il.

Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized by the Boston Business Journal as one of the Best Places to Work for the second year in a row. Surface was among 20 companies selected in the “small” category with 50 to 99 Massachusetts-based employees.

Surface Oncology Named one of the 2022 Best Places to Work by Boston Business Journal

Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche

Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Poster presentation highlights translational work supporting recommended dosing for SRF388 Phase 2 trials Poster presentation highlights translational work supporting recommended dosing for SRF388 Phase 2 trials

Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Surface's board of directors granted Theresa Boni, J.D., general counsel and senior vice president, legal, non-qualified stock options to purchase 120,000 shares of the company's common stock with a per share exercise price of $2.87, the closing price of Surface's common stock as reported by Nasdaq on April 1, 2022.

Surface Oncology Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the first patient has been dosed by GlaxoSmithKline (GSK) in the Phase 1 study of GSK4381562 in patients with solid tumors. GSK4381562 is a fully human IgG1 antibody targeting PVRIG, an inhibitory protein expressed on natural killer cells (NK cells) and T cells.

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Theresa Boni, J.D., as general counsel and senior vice president, legal. Ms. Boni has more than 20 years of legal experience spanning the biopharmaceutical and medical device industries.

Surface Oncology Appoints Theresa Boni as General Counsel

Paramount Gold Nevada

VEON

What you need to know about trading penny stocks on March 11th The post Trading Penny Stocks? Top Stock Market News for March 11th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 11th, 2022

Surface Oncology (SURF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Surface Oncology (SURF) Might Surprise This Earnings Season

Continued progress advancing next-generation antibody portfolio, with ongoing clinical trials evaluating the broad potential of SRF388 and SRF617 across multiple tumor types

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021

Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Surface Oncology, Inc. (SURF) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in the “Novel Immuno-Oncology” panel discussion at Cowen's 42nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m. ET.

Surface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen's 42nd Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that company management will participate in a fireside chat during Citi's 2022 Virtual Immuno-Oncology Summit.

Surface Oncology to Participate in Citi's 2022 Virtual Immuno-Oncology Summit

Archer Aviation

Compugen

Joby Aviation

Nano Dimension

Quantum-Si

Skillz

Cathie Wood stocks to watch right now. The post 7 Penny Stocks To Buy Based On Cathie Wood's ARK Invest Holdings appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Penny Stocks To Buy Based On Cathie Wood's ARK Invest Holdings

GlaxoSmithKline

Novartis

SURF is an early-stage cancer therapeutics company with multiple big pharma partnerships.

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Biopharma veteran Ben Hickey appointed to Board of Directors

Surface Oncology Appoints Denice Torres as Chair of the Board of Directors

Gastric cancer trial in combination with pembrolizumab currently enrolling; first-line combination cohort for pancreatic cancer planned Gastric cancer trial in combination with pembrolizumab currently enrolling; first-line combination cohort for pancreatic cancer planned

News for Surface Oncology Inc Stock (SURF)